blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3586871

EP3586871 - RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  05.12.2019
Database last updated on 02.09.2024
Most recent event   Tooltip26.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
CureVac SE
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2023/01]
Former [2021/10]For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
Former [2020/01]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / Kramps, Thomas
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
02 / Schnee, Margit
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
03 / Voß, Daniel
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
04 / Petsch, Benjamin
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
 [2020/41]
Former [2020/01]01 / Kramps, Thomas
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
02 / Schnee, Margit
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
03 / Voß, Daniel
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
04 / Petsch, Benjamin
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
Representative(s)Graf von Stosch Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2020/01]
Application number, filing date19173393.021.08.2014
[2020/01]
Priority number, dateWO2013EP0251821.08.2013         Original published format: PCT/EP2013/002518
[2020/01]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3586871
Date:01.01.2020
Language:EN
[2020/01]
Type: A3 Search report 
No.:EP3586871
Date:11.03.2020
Language:EN
[2020/11]
Search report(s)(Supplementary) European search report - dispatched on:EP11.02.2020
ClassificationIPC:A61K39/155, A61P31/14
[2020/01]
CPC:
A61K39/12 (EP); A61P31/14 (EP); A61K2039/53 (EP);
A61K2039/55516 (EP); C12N2760/18534 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/01]
TitleGerman:IMPFSTOFF GEGEN DAS RESPIRATORISCHE SYNZYTIALVIRUS[2020/01]
English:RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE[2020/01]
French:VACCIN CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL (RSV)[2020/01]
Examination procedure08.05.2019Examination requested  [2020/01]
11.09.2020Amendment by applicant (claims and/or description)
Parent application(s)   TooltipEP14755336.6  / EP3035960
Fees paidRenewal fee
08.05.2019Renewal fee patent year 03
08.05.2019Renewal fee patent year 04
08.05.2019Renewal fee patent year 05
17.07.2019Renewal fee patent year 06
30.06.2020Renewal fee patent year 07
16.08.2021Renewal fee patent year 08
22.08.2022Renewal fee patent year 09
22.08.2023Renewal fee patent year 10
26.08.2024Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2006015789  (GENEART GMBH [DE], et al) [Y] 1-24 * abstract *;
 [Y]WO2006050280  (CENTOCOR INC [US], et al) [Y] 1-24 * page 17; sequence 1 *;
 [XY]WO2012019630  (CUREVAC GMBH [DE], et al) [X] 1 * Abstract * claims 1, 2, 13 * Fig. 8 * [Y] 2-24;
 [XY]WO2012116714  (CUREVAC GMBH [DE], et al) [X] 1,2,19-22 * pp. 18-27, 60 * [Y] 3-20,23,24;
 [Y]WO2012116715  (CUREVAC GMBH [DE], et al) [Y] 1-24 * page 24 - page 26 *;
 [Y]  - BENJAMIN PETSCH ET AL, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", NATURE BIOTECHNOLOGY, (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 1087-0156, pages 1210 - 1216, XP055051005 [Y] 1-24 * Abstract * Discussion * Online Methods *

DOI:   http://dx.doi.org/10.1038/nbt.2436
 [A]  - SCHLAKE THOMAS ET AL, "Developing mRNA-vaccine technologies.", RNA BIOLOGY NOV 2012, (201211), vol. 9, no. 11, ISSN 1555-8584, pages 1319 - 1330, XP055098782 [A] 1-24

DOI:   http://dx.doi.org/10.4161/rna.22269
 [A]  - FOTIN-MLECZEK MARIOLA ET AL, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.", THE JOURNAL OF GENE MEDICINE JUN 2012, (201206), vol. 14, no. 6, ISSN 1521-2254, pages 428 - 439, XP002719717 [A] 1-24

DOI:   http://dx.doi.org/10.1002/jgm.2605
 [Y]  - BAUER ASLI PETRA ET AL, "The impact of intragenic CpG content on gene expression.", NUCLEIC ACIDS RESEARCH JUL 2010, (201007), vol. 38, no. 12, ISSN 1362-4962, pages 3891 - 3908, XP002719888 [Y] 1-24 * abstract *

DOI:   http://dx.doi.org/10.1093/nar/gkq115
 [Y]  - OOMENS ANTONIUS G P ET AL, "The cytoplasmic tail of the human respiratory syncytial virus F protein plays critical roles in cellular localization of the F protein and infectious progeny production.", JOURNAL OF VIROLOGY NOV 2006, (200611), vol. 80, no. 21, ISSN 0022-538X, pages 10465 - 10477, XP002719889 [Y] 1-24 * Materials and methods *

DOI:   http://dx.doi.org/10.1128/JVI.01439-06
 [T]  - HIGGINS DEBORAH ET AL, "Advances in RSV vaccine research and development - A global agenda", VACCINE, ELSEVIER, AMSTERDAM, NL, (20160419), vol. 34, no. 26, doi:10.1016/J.VACCINE.2016.03.109, ISSN 0264-410X, pages 2870 - 2875, XP029560780 [T] * figure 1 *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2016.03.109
 [A]  - ANDERSON L J ET AL, "Strategic priorities for respiratory syncytial virus (RSV) vaccine development", VACCINE, ELSEVIER, AMSTERDAM, NL, (20130416), vol. 31, doi:10.1016/J.VACCINE.2012.11.106, ISSN 0264-410X, XP028579217 [A] 1-24 * paragraph [04.2] *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2012.11.106
 [Y]  - BART G. JONES ET AL, "Sendai virus-based RSV vaccine protects African green monkeys from RSV infection", VACCINE, AMSTERDAM, NL, (20120101), vol. 30, no. 5, doi:10.1016/j.vaccine.2011.11.046, ISSN 0264-410X, pages 959 - 968, XP055471614 [Y] 1-24 * figure 6 *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.11.046
by applicantWO9640945
 WO2008077527
 WO2008077592
 WO2009030481
 WO2010037539
 WO2011026641
 WO2012013326
 WO2012019780
 WO2012113513
 WO2013143700
    - SHAW et al., Curr Opin Virol., (20130600), vol. 3, no. 3, pages 332 - 42
    - HIGH-RISK INFANTS, Pediatrics, vol. 102, no. 3, pages 531 - 537
    - TABLAN, "Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee", Recommendations and Reports / Centers for Disease Control, (20030000), vol. 53, no. 3, pages 1 - 36
    - SINGH, S.R. et al., "Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model", Vaccine, (20070000), vol. 25, no. 33, doi:doi:10.1016/j.vaccine.2007.05.068, pages 6211 - 6223, XP022168621

DOI:   http://dx.doi.org/10.1016/j.vaccine.2007.05.068
    - ZHAN, X. et al., "Respiratory syncytial virus (RSV) F protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B", Vaccine, (20070000), vol. 25, no. 52, pages 8782 - 8793, XP022374863
    - VAUGHAN, K. et al., "DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys", Vaccine, (20050000), vol. 23, no. 22, doi:doi:10.1016/j.vaccine.2004.10.046, pages 2928 - 2942, XP004797066

DOI:   http://dx.doi.org/10.1016/j.vaccine.2004.10.046
    - LIU, J. et al., "Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection", Journal of Virology, (20100000), vol. 84, no. 20, doi:doi:10.1128/JVI.00963-10, pages 10501 - 10509, XP055000829

DOI:   http://dx.doi.org/10.1128/JVI.00963-10
    - KARLIN et al., PNAS USA, (19930000), vol. 90, pages 5873 - 5877
    - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402
    - OOMENS et al., J. Virol., (20060000), vol. 80, no. 21, pages 10465 - 77
    - "GenBank", Database accession no. U26404
    - LAI et al., Development, (19950000), vol. 121, pages 2349 - 2360
    - "GenBank", Database accession no. X65327
    - "GenBank", Database accession no. NM_000477.5
 WO2012EP02448
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.